Airport COVID -19 Testing Lab from BGI Safeguards Ethiopia-China Route

From April to August, 2021, BGI’s COVID-19 testing lab has helped 5,500 Chinese travelers safely fly out of  the Addis Ababa Bole International Airport. In April, BGI set up the “Huo-Yan” laboratory, a COVID-19 testing lab, at the airport for passengers flying to China in cooperation with Ethiopia Airlines. Since then, the lab has contributed to around five consecutive months without a single flight suspension on the route.

The pre-flight testing procedures pioneered at the lab present an option for reducing the pressure of containment measures at destinations.

The lab provides quick, accurate nucleic acid polymerase chain reaction (PCR) testing and antibody testing services to passengers at the Airport. The lab can test up to 400 samples within three hours and 5,000 samples per day, reducing inconvenience for departing and transiting at the Airport.

The lab helps reduce imported cases. Passengers are required to quarantine first. They are not allowed to board until obtaining negative results for both a COVID-19 nucleic acid PCR test and an antibody test.

Since the start of operations at the lab, the number of outbound positive cases found on arrival has sharply decreased. To date, no flights have been suspended between Ethiopia and China, making this the only direct flight from the African continent to China that has been continuously operating during this period.

“From April 21 to August 31, the laboratory has provided testing services for more than 5,500 passengers on 19 flights to China,” said Chen Songheng, the head of the “Huo-Yan” laboratory in Ethiopia.

BGI has built more than 30 “Huo-Yan” laboratories with partners in over 80 countries and regions. By providing one-platform solutions with accurate, efficient testing, the labs play a vital role in contributing to the global fight against the COVID-19 pandemic.

BGI leads innovative development in genomics and life sciences. Through its integrated model, it incorporates industry development, education and research in compliance with international bioethical protocols. It applies frontier multi-omics research findings to areas including medicine, healthcare and resource conservation, and provides cutting-edge proprietary life science instruments and devices, technical support and solutions to revolutionize the current healthcare system towards precision medicine and healthcare.

SourceBGI

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”